Lipoprotein(a)/CD36 Interaction Drives IL-6/RhoA-GTP Signaling and miRNA Epigenetic Regulation in Coronary Artery Spasm
<b>Background:</b> Lipoprotein(a) [Lp(a)]-induced inflammation contributes to coronary artery spasm (CAS) by the contraction of vascular smooth muscle cells. However, the interaction between Lp(a) and soluble CD36 (sCD36)/interleukin (IL)-6/RAS Homolog Family Member A (RhoA)-GTP signaling pathway has not been evaluated. <b>Methods:</b> We investigated the relevance of Lp(a)/CD36 signaling in CAS patient monocyte-derived macrophages (PMDMs) and a human coronary artery smooth muscle cell (HCASMC) line using expression profile correlation analyses, molecular docking, RNA sequencing, flow cytometry, immunoblotting, and quantitative reverse transcription polymerase chain reaction. <b>Results:</b> Plasma Lp(a) and sCD36 levels in 41 CAS patients were significantly higher (<i>p</i> = 0.001) and positively correlated (r<sup>2</sup> = 0.3145, <i>p</i> < 0.001), a trend not observed in 36 non-CAS controls. RNA sequencing indicated a significant co-overexpression of CD36 and RhoA in Lp(a)-treated CAS PMDMs and HCASMCs, of which the mRNA and protein expression of CD36 and RhoA were significantly enhanced (<i>p</i> < 0.001) dose-dependently. Lp(a) rather than LDL preferentially induced CD80+ PMDM (M1) polarization. In HCASMCs, the CD36 knockdown using either short hairpin RNA or natural biflavonoid amentoflavone suppressed Lp(a)-upregulated protein expression of CD36, RhoA-GTP, IL-6, tumor necrosis factor (TNF)-α, nuclear factor (NF)-κB, and CD80; however, overexpressed CD36 increased their levels. Lp(a) decreased and amentoflavone increased the epigenetic expression of CD36 inhibitors, miR-335-5p, and miR-448, respectively. Reciprocally, an miRNA inhibitor or mimic could magnify or diminish Lp(a)-induced CD36, TNF-α, NF-κB and IL-6 expressions in HCASMCs, respectively. <b>Conclusions:</b> Elevated Lp(a) levels upregulate the CD36-dependent TNF-α/NF-κB/IL-6/RhoA-GTP signaling pathway in CAS PMDMs and HCASMCs, indicating that Lp(a)/CD36 inflammatory signaling, HCASMC activation, and macrophage M1 polarization mediate CAS development.
Authors
- Chi‐Tai Yeh (ORCID: https://orcid.org/0000-0001-5189-9755)
- Iat-Hang Fong (ORCID: https://orcid.org/0000-0002-8235-0877)
- Nicholas G. Kounis (ORCID: https://orcid.org/0000-0002-9751-6710)
- Yen‐Kuang Lin (ORCID: https://orcid.org/0000-0002-7027-9508)
- Kuang-Tai Kuo (ORCID: https://orcid.org/0000-0003-2754-2283)
- Vijesh Kumar Yadav (ORCID: https://orcid.org/0000-0002-2679-1205)
- Tsung‐Han Hsieh (ORCID: https://orcid.org/0000-0002-2268-9246)
- Patrick Hu (ORCID: https://orcid.org/0000-0003-3675-7753)
- Ming Yow Hung
Institutions
- University of California, Riverside (US)
- University of Patras (GR)
- National Taitung University (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
- National Taiwan Sport University (TW)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3390/ph18091384
- Citations
- 1
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- National Science Council
- Taipei Medical University
- National Science and Technology Council
- Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare